JORGE E CORTES to Antineoplastic Protocols
This is a "connection" page, showing publications JORGE E CORTES has written about Antineoplastic Protocols.
Connection Strength
0.163
-
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591.
Score: 0.140
-
Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
Score: 0.023